The oncology therapy developer has gone public in an upsized offering that provided an exit to Third Rock Ventures.
Relay Therapeutics, a US-based oncology therapy developer based on research from multiple institutions, went public yesterday in a $400m initial public offering.
The company increased the number of shares in the offering from 14.7 million to 20 million and priced the shares at $20.00 each, above the IPO’s $16 to $18 range. Its shares closed at $35.05 on their first day of trading on the Nasdaq Global Market yesterday, valuing it above $3bn.
Founded in 2016, Relay…
